Marla Lipsyc-Sharf

11PUBLICATIONS
101CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsHealth and ecological risk assessmentCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 24, 2026
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

|Jul 13, 2026
Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape.

|Jul 13, 2026
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

|Nov 07, 2025
Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.

Maxwell R Lloyd, Caroline M Weipert, Azka Ali

|Sep 09, 2025
Pregnancy and breast cancer in young women: current updates and future directions.

Shiliang Zhang, Sena B Guclu, Marla Lipsyc-Sharf

|Jan 08, 2024
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.

Stefania Morganti, Christopher J Gibson, Qingchun Jin

Pageof 2

Frequent Collaborators

4 joint publications

Sara M Tolaney

3 joint publications

Heather Parsons

3 joint publications

Ann Partridge

2 joint publications

Katheryn Santos